Virpax Pharmaceuticals, INC 8-K filings

Virpax Pharmaceuticals has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, triggering a compliance period to avoid delisting.

Virpax Pharmaceuticals has announced the pricing of a public offering to raise approximately $2.25 million through the sale of common stock and warrants.

Virpax Pharmaceuticals announced its first quarter 2024 financial results, highlighting progress in its drug development programs and recent study outcomes.

Virpax Pharmaceuticals has entered into a separation agreement with its Chief Medical Officer, Jeffrey Gudin, MD, who will be resigning from his position but will remain a Class III Director.

Virpax Pharmaceuticals reports successful Maximum Tolerated Dose study results for Probudur, a liposomal bupivacaine formulation aimed at providing both immediate and sustained pain relief.

Virpax Pharmaceuticals received a notification from Nasdaq for not meeting the minimum stockholders' equity requirement, placing its listing status at risk.

Virpax Pharmaceuticals announced its 2023 year-end financial results, highlighting progress in clinical trials, regulatory submissions, and strategic partnerships.

Virpax Pharmaceuticals has regained compliance with Nasdaq listing rules and settled a legal dispute with Sorrento Therapeutics and Scilex Pharmaceuticals.

Virpax Pharmaceuticals will enact a 1-for-10 reverse stock split to regain Nasdaq compliance and has settled a lawsuit with Sorrento and Scilex for $6 million plus royalties.